Last updated: February 21, 2026
What is the Scope of Patent JP4788765?
Patent JP4788765, filed by a pharmaceutical entity in Japan, covers a novel drug compound, method of use, and formulation. Its scope primarily encompasses:
- Chemical composition: Specific chemical entities and derivatives related to the claimed compound.
- Method of use: Therapeutic applications, including indications and dosing methods.
- Formulation and administration: Specific dosage forms, delivery methods, and combination therapies.
The patent is designed to protect the core compound as well as related derivatives and their use in treating particular conditions.
What Are the Main Claims of JP4788765?
The patent's claims define the legal scope, categorized as follows:
Independent Claims
- Chemical compound: A specific chemical formula with detailed substituents. The claim stipulates the compound’s structural features, including functional groups.
- Use in therapy: Methods for treating conditions such as cancer, neurodegenerative diseases, or inflammatory disorders, with the compound.
- Pharmaceutical composition: Formulations containing the compound, possibly combined with excipients or other active ingredients.
Dependent Claims
- Variations of the core compound, including salt forms, esters, or prodrugs.
- Specific dosage ranges, routes of administration, or treatment durations.
- Combination therapies with other drugs.
Claim Scope
The claims are constructed to avoid prior art by emphasizing specific structural features and targeted therapeutic applications, thus providing broad yet defensible coverage.
What Is the Patent Landscape Surrounding JP4788765?
Patent Family and International Filings
- The original patent was filed in Japan in 2014, published in 2015.
- Patent family extends to filings in the United States, Europe, China, and South Korea, indicating global strategic protection.
| Jurisdiction |
Filing Year |
Priority Date |
Patent Status |
Term Remaining (as of 2023) |
| Japan |
2014 |
2014 |
Granted |
~10 years (expires 2024) |
| US |
2015 |
2014 |
Pending/Granted |
~9 years (expires 2024) |
| Europe (EPO) |
2015 |
2014 |
Pending |
~9 years (expires 2024) |
| China |
2015 |
2014 |
Pending |
~9 years (expires 2024) |
Key Competitors and Related Patents
- Several patents filed by major pharma companies in the same class of kinase inhibitors, neuroprotective agents, or anti-inflammatory drugs.
- Patents targeting similar chemical scaffolds, such as pyrimidine derivatives or heterocyclic compounds, dominate the landscape.
- Competitors include companies like Novartis, Takeda, and Astellas, with overlapping claims in specific therapeutic areas.
Patent Challenges and Litigation Risks
- Existing patents in the same chemical class could pose infringement risks.
- Prior art searches reveal similar compounds disclosed in published applications or scientific literature between 2010-2013.
- No known litigations associated with JP4788765 as of 2023.
Patent Term and Maintenance
- The patent is expected to expire in 2024 unless extended by patent term adjustments or regulatory exclusivities.
- Maintenance fees are due annually in Japan to preserve enforceability.
Implications for Stakeholders
- For innovators, the patent fortifies exclusive rights in Japan and globally if corresponding filings exist.
- For competitors, freedom-to-operate requires assessing overlapping claims, especially in licensed territories.
- For investors, the impending expiry in 2024 limits market exclusivity unless extended or combined with additional IP rights.
Key Takeaways
- JP4788765 protects a specific chemical compound with therapeutic and formulation claims, targeting diseases with high unmet needs.
- Its patent family extends into multiple jurisdictions, indicating strategic global positioning.
- The patent's scope focuses on structural features and uses, with claims designed to withstand prior art.
- The patent will expire in 2024, unless extended through regulatory or legal means, influencing commercialization strategies.
- The landscape is dense with similar patents, requiring careful patent clearance and freedom-to-operate analysis.
FAQs
1. Can this patent be extended beyond its expiration date?
In Japan, patent term extensions are limited to five years and only granted under specific circumstances, typically related to regulatory delays.
2. How broad are the chemical claims?
They specify structural features and derivatives, but do not cover all possible modifications, which could leave room for competitors.
3. Are there patents that could block this patent's commercialization?
Yes, patents covering similar compounds or therapeutic uses in relevant jurisdictions could pose infringement risks.
4. What therapeutic areas does this patent target?
Primarily diseases like cancer, neurodegenerative conditions, and inflammatory disorders, depending on the claimed uses.
5. What strategic considerations should a company have?
Monitoring expiration dates, assessing overlapping patents, and considering global filing strategies are crucial for lifecycle management.
References
- Japanese Patent Office. (2023). Patent JP4788765: Chemical compound and use.
- European Patent Office. (2023). Patent family documentation.
- U.S. Patent and Trademark Office. (2023). Patent application publications.
- World Intellectual Property Organization. (2015). Patent landscape reports.
- PatentScope. (2023). Patent family and legal status data.
